-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net...
-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net...
-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr....
BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty...
BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty...
Third quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales Expansion of Upneeq launch continues with...
BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty...
BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty...
BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty...
BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty...